Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly

NCT00725231 is registered in ClinicalTrials.gov with University of Göttingen as lead sponsor.

NCT NCT00725231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00725231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly
Lead sponsor
University of Göttingen
Phase
Phase 3
Overall status
Unknown status
Start date
February 29, 2008
Completion date
March 31, 2014
Enrollment
274 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic lymphadenopathy, extranodal nk/t-cell lymphoma, peripheral t cell lymphoma, unspecified